Amarin Corp Plcuk (AMRN) Non Operating Income (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Non Operating Income of $188000.0 for Q1 2026, down 25.69% year-over-year from $253000.0 in Q1 2025, and down 93.53% quarter-over-quarter from $2.9 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Non Operating Income (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Non Operating Income data on file, last reported at $188000.0 in Q1 2026.
- Non Operating Income for Q1 2026 came in at $188000.0, down 25.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (up 3668.89% YoY), and the FY2025 annual result was $3.3 million, up 172.77% from the prior year.
- Non Operating Income fell to $188000.0 in Q1 2026 per AMRN's latest filing, from $2.9 million in the prior quarter.
- Over five years, Non Operating Income peaked at $5.0 million in Q4 2023 and troughed at -$2.3 million in Q2 2022.
- A 5-year average of $704058.8 and a median of $253000.0 in 2025 frame the typical range for Non Operating Income.
- On a YoY basis, Non Operating Income climbed as much as 1320.45% in 2022 and fell as far as 1080.63% in 2022.
- A 5-year view of Non Operating Income shows it stood at $1.2 million in 2022, then soared by 296.0% to $5.0 million in 2023, then tumbled by 115.21% to -$753000.0 in 2024, then surged by 485.66% to $2.9 million in 2025, then tumbled by 93.53% to $188000.0 in 2026.
- Business Quant data shows AMRN's Non Operating Income at $188000.0 in Q1 2026, $2.9 million in Q4 2025, and $205000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 195.49 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -65.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -294.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -2.31 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -32.00 Mn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 2.90 Mn |
| Sep 30, 2025 | 205,000.00 |
| Jun 30, 2025 | -85,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Dec 31, 2024 | -753,000.00 |
| Sep 30, 2024 | 265,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 4.95 Mn |
| Sep 30, 2023 | -575,000.00 |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | 624,000.00 |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 511,000.00 |
| Jun 30, 2022 | -2.26 Mn |
| Mar 31, 2022 | -246,000.00 |
| Dec 31, 2021 | 88,000.00 |
| Sep 30, 2021 | -57,000.00 |
| Jun 30, 2021 | -191,000.00 |